Lymphoma

The addition of radiotherapy to CAR T-cell therapy may particularly benefit patients with localized disease, according to Timothy Robinson, MD, PhD.

Timothy Robinson, MD, PhD, discusses how radiation may play a role as bridging therapy to CAR T-cell therapy for patients with relapsed/refractory DLBCL.

The FDA has set a Prescription Drug User Fee Act date in the first quarter of 2025 for the potential approval of acalabrutinib in previously untreated MCL.

Nausheen Ahmed, MD, discusses the FDA REMS mandate to help assess toxicity in patients receiving CAR T-cell therapy.

Complete responses were observed in a small cohort of patients with DLBCL who have previously received autologous CAR T-cell therapy.

Treatment with valemetostat yields responses across all PTCL subtypes in the phase 2 VALENTINE-PTCL01 trial.

Efficacy, safety, time, and cost were all factors assessed between subcutaneous and intravenous rituximab for patients with non-Hodgkin lymphoma.

The European Commission’s decision represents the first regulatory approval of odronextamab for patients with follicular lymphoma or DLBCL.

Brentuximab vedotin plus chemotherapy significantly improved HRQOL in both pediatric and young adult patients with high-risk Hodgkin lymphoma.

The approval of epcoritamab may impact treatment options in the R/R follicular lymphoma space, according to Tycel Phillips, MD.

Pallawi Torka, MD, and the Oncology Brothers discuss the therapeutic landscape for patients with relapsed/refractory mantle cell lymphoma.

A hematologist-oncologist provides comprehensive insights on the treatment of newly diagnosed patients with mantle cell lymphoma.

The Oncology Brothers and Pallawi Torka, MD, review treatment options for patients with relapsed/refractory follicular lymphoma.

Pallawi Torka, MD, joins the Oncology Brothers to discuss patient workup and treatment practices in follicular lymphoma, highlighting the PRIMA study and the role of maintenance therapy.

Conditional marketing authorization for epcoritamab in the European Union is based on findings from the phase 1/2 EPCORE NHL-1 trial.

In Japan, liso-cel recently received approval for patients with previously treated relapsed/refractory follicular lymphoma.

Developers plan to submit a sBLA for tafasitamab in relapsed/refractory follicular lymphoma based on data from the inMIND trial.

Medical oncologists conclude their discussion with a review of the toxicity profiles of treatments for diffuse large B-cell lymphoma.

Carla Casulo, MD, and the Oncology Brothers review the treatment algorithm for patients with relapsed/refractory DLBCL.

The Oncology Brothers and Carla Casulo, MD, discuss treatment practices for patients with stage III or IV diffuse large B-cell lymphoma.

A hematologist-oncologist joins the Oncology Brothers do discuss first-line treatment practices for patients with stage I or II diffuse large B-cell lymphoma.

Carla Casulo, MD, joins Rahul Gosain, MD, and Rohit Gosain, MD, to provide clinical insights on biopsy practices and discuss the importance of cell of origin in treating diffuse large B-cell lymphoma (DLBCL).

Targeting multiple survival pathways simultaneously with ViPOR may be effective in specific molecular subtypes of relapsed/refractory DLBCL.

Reduction of long-term survival following CAR T-cell therapy associated with late infections and SMN development was observed, especially in elderly patients.

After a complete response letter and a subsequent biologics license application resubmission, denileukin diftitox has been approved by the FDA.